Document Detail


Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease.
MedLine Citation:
PMID:  17344923     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Prolonged use of parenteral nutrition (PN) in neonates can lead to parenteral nutrition-associated liver disease (PNALD), manifested by elevated direct bilirubin concentrations, and in some cases progressing to hepatic failure. When new potential means of preventing PNALD in the neonatal intensive care unit (NICU), such as Omegaven usage, are tested in clinical trials, the studies should enroll neonates at a very high risk of developing PNALD. However, it is not always clear, in the first days of life, which neonates are most likely to develop PNALD. Therefore, preparatory to devising studies of prophylaxis against PNALD, we conducted an evaluation of all NICU patients who received PN for >or=14 day, assessing their likelihood of developing PNALD. METHODS: We performed an historic cohort analysis of all neonates in the Intermountain Healthcare system, receiving PN for 14 days or more during their stay, with dates of birth between 1 January, 2002 and 30 June, 2006. RESULTS: During the 4(1/2)-year period, 9861 neonates were cared for in the Intermountain Healthcare NICUs. Of these, 9547 (96.8%) survived for at least 28 days, and of these 6543 (68.5%) received PN. Twenty-one percent (1366 patients) of those receiving PN, received it for >or=14 days. PNALD was ascertained in this group by a direct bilirubin >or=2.0 mg/dl. Neonates receiving PN for 14-28 days had a 14% incidence of PNALD, those receiving PN for 29-56 days had a 43% incidence, those receiving PN for 57-100 days had a 72% incidence and those receiving PN for >100 days had a 85% incidence. Groups of patients identifiable on the first day of life as having the highest risk of developing PNALD were birth weight <500 g (odds ratio (OR), 30.7), birth weight 500-749 g (OR, 13.1), gastrochisis (OR, 20.3) and jejunal atresia (OR, 24.0). Among 357 patients who developed PNALD, the highest direct bilirubin concentrations correlated with the highest serum alkaline phosphatase and transaminase concentrations. Deaths after 28 days were much more common in those with the highest direct bilirubin and transaminase concentrations (P<0.0001). CONCLUSIONS: In the first days of life, certain NICU patients can be identified as being at very high risk for developing PNALD. These are patients <750 g birth weight, those with gastrochisis and those with jejunal atresia. We speculate that these groups would be reasonable subjects for including in a PNALD prophylaxis trial, testing new preventative strategies such as Omegaven usage.
Authors:
R D Christensen; E Henry; S E Wiedmeier; J Burnett; D K Lambert
Related Documents :
6502373 - Rectal or axillary temperature measurement: effect on plasma bilirubin and intestinal t...
8479173 - Impaired response to alloantigens in murine biliary obstruction.
23637453 - Personhood, harm and interest: a reply to alberto giubilini and francesca minerva.
Publication Detail:
Type:  Journal Article     Date:  2007-03-08
Journal Detail:
Title:  Journal of perinatology : official journal of the California Perinatal Association     Volume:  27     ISSN:  0743-8346     ISO Abbreviation:  J Perinatol     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-04-24     Completed Date:  2007-08-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8501884     Medline TA:  J Perinatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  284-90     Citation Subset:  IM    
Affiliation:
Intermountain Healthcare, Salt Lake City, UT, USA. rdchris4@ihc.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cohort Studies
Fat Emulsions, Intravenous / adverse effects
Female
Hospital Mortality
Humans
Infant, Newborn
Infant, Premature, Diseases / etiology*,  mortality
Infant, Very Low Birth Weight
Intensive Care, Neonatal*
Jaundice, Neonatal / diagnosis,  etiology*,  mortality
Liver Failure / diagnosis,  etiology*,  mortality
Liver Function Tests
Long-Term Care
Male
Neonatal Screening*
Parenteral Nutrition, Total / adverse effects*
Retrospective Studies
Risk Factors
Survival Rate
Utah
Chemical
Reg. No./Substance:
0/Fat Emulsions, Intravenous

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgro...
Next Document:  Serum amyloid A: an early and accurate marker of neonatal early-onset sepsis.